Kornilaeva, G.V.G.V.KornilaevaSiniavin, A.E.A.E.SiniavinSchultz, AnkeAnkeSchultzGermann, AnjaAnjaGermannMoog, C.C.MoogBriesen, Hagen vonHagen vonBriesenTurgiev, A.S.A.S.TurgievKaramov, E.V.E.V.Karamov2022-03-0617.10.20192019https://publica.fraunhofer.de/handle/publica/25962210.24406/publica-r-25962210.32607/20758251-2019-11-2-68-76The anti-HIV activity of a new humic substance-derived preparation has been studied in individual pools of immune cells (CD4+ T lymphocytes, macrophages, dendritic cells). Near-complete inhibition of the HIV infection (by more than 90%) was achieved by treating each of the abovementioned cell types with non-toxic concentrations of the preparation. The inhibitory effect demonstrates the possibility of preventing the depletion of a significant portion of functionally important immune cells. A comparative study of infection inhibition in individual cell pools has allowed us to reveal the differences in the preparation's effectiveness in each of the cell populations. A R5-tropic HIV-1 infection in macrophages exhibited maximum sensitivity to the preparation: 90% and 50% inhibition of the infection were observed in the presence of concentrations as low as 1.4 and 0.35 mg/ml, respectively. A 15- and 19-fold higher concentration was required to achieve the same extent of inhibition in dendritic cells infected with the same strain. The effectiveness of the drug in CD4 + T lymphocytes is quite comparable to its effectiveness in macrophages. The drug is universally effective for both the T- and M-tropic variants of HIV-1.en610620journal article